Hematopoiesis News Volume 14.34 | Aug 29 2023

    By
    Jamie Kang
    -
    0
    13







    2023-08-29 | HN 14.34


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.34 – 29 August, 2023
    TOP STORY

    RBFOX2 Recognizes N6-Methyladenosine to Suppress Transcription and Block Myeloid Leukaemia Differentiation

    Scientists presented a pathway of m6A methyltransferase complex recruitment and m6A deposition on chromatin-associated RNAs, resulting in locus-selective chromatin regulation, which has potential therapeutic implications in leukemia.
    [Nature Cell Biology]

    Full Article
    Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
    PUBLICATIONSRanked by the impact factor of the journal

    Cdc73 Protects Notch-Induced T Cell Leukemia Cells from DNA Damage and Mitochondrial Stress

    To find alternative ways to target Notch signals, researchers investigated cell division cycle 73 (Cdc73), which is a Notch cofactor and key component of the RNA polymerase-associated transcriptional machinery, an emerging target in T cell acute lymphoblastic leukemia.
    [Blood]

    Abstract

    Convergent Somatic Evolution Commences In Utero in a Germline Ribosomopathy

    Investigators performed whole genome sequencing of 323 hematopoietic colonies from 10 individuals with the inherited ribosomopathy Shwachman-Diamond syndrome to reconstruct hematopoietic phylogenies.
    [Nature Communications]

    Full Article

    Hematopoietic-Specific Heterozygous Loss of Dnmt3a Exacerbates Colitis-Associated Colon Cancer

    Scientists hypothesized that bone marrow–derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in clonal hematopoiesis, contributed to the pathogenesis of colon cancer.
    [Journal Of Experimental Medicine]

    Full Article
    Graphical Abstract

    Autophagy Preserves Hematopoietic Stem Cells by Restraining MTORC1-Mediated Cellular Anabolism

    Researchers addressed why autophagy depletion led to a drastic loss of the stem cell compartment. Using inducible deletion of autophagy specifically in adult HSCs and in mice chimeric for autophagy-deficient and normal HSCs, they demonstrated that the stem cell loss was cell-intrinsic.
    [Autophagy]

    Full Article

    miR-126 Identifies a Quiescent and Chemo-Resistant Human B-ALL Cell Subset That Correlates with Minimal Residual Disease

    Investigators exploited patient-derived xenograft models with B cell acute lymphoblastic leukemia (B-ALL) cells transduced with a miR-126 reporter allowing the prospective isolation of miR-126(high) cells for their functional and transcriptional characterization.
    [Leukemia]

    AbstractGraphical Abstract

    Feasibility of Peripheral Blood Stem Cell Collection from Sickle Cell Trait Donors with an Intensified G-CSF Regimen

    In this retrospective analysis, researchers compared the safety and efficacy of peripheral stem cell mobilization with a G-CSF intensified mobilization regimen in sickle cell trait donors with a conventional G-CSF mobilization regimen in healthy donors.
    [European Journal Of Haematology]

    Full Article

    Phase I Study Evaluating the FC-Optimized FLT3 Antibody FLYSYN in AML Patients with Measurable Residual Disease

    This first-in-human, open-label, single-arm, multicenter trial included AML patients in complete remission with persisting or increasing measurable residual disease and evaluated safety/tolerability, pharmacokinetics and preliminary efficacy of FLYSYN at different dose levels administered intravenously.
    [Journal Of Hematology & Oncology]

    Full Article

    Autologous Stem Cell Transplantation in Adult Patients with Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission and No Detectable Minimal Residual Disease. A Comparative Retrospective Study with Haploidentical Transplants of the Global Committee and the ALWP of the EBMT

    Researchers compared the outcome post autologous stem cell transplantation or haploidentical transplants in patients with intermediate-risk acute myeloid leukemia achieving first complete remission and measurable residual disease negativity at pretransplant in the period from 2010 to 2021.
    [Bone Marrow Transplantation]

    Full Article
    Image of man completing the on-demand CFU assay course on his laptop.
    REVIEWS

    Red Blood Cells: A Potential Delivery System

    The authors compared the various physiological and physical characteristics of RBCs, analyzed their potential advantages in delivery systems, and summarized their existing practices in biomedicine.
    [Journal Of Nanobiotechnology]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Fulcrum’s Sickle Cell Disease Program Is Back in Business after FDA Lifts 6-Month Hold

    After a six-month wait, Fulcrum Therapeutics’ sickle cell disease plans are back on track after the FDA lifted a hold on the biotech’s candidate. The regulator instigated the full clinical hold on the therapy, dubbed FDX-6058, back in February.
    [Fierce Biotech]

    Editorial

    US Patent Granted Providing Broad Protection for BVX001

    BiVictriX Therapeutics plc announced that the United States Patent and Trademark Office has granted a patent providing broad protection for BVX001. The claims granted within this patent provide broad protection for the lead therapeutic asset, BVX001, at the antigen level.
    [BiVictriX]

    Press Release
    FEATURED EVENT

    Seventh International Cancer Immunotherapy Conference: Translating Science into Survival

    September 20 – 23, 2023
    Milan, Italy

    > See All Events

    JOB OPPORTUNITIES

    Research Fellowship – Biochemical Mechanisms of Blood Coagulation

    Center for Biologics Evaluation and Research – Silver Spring, Maryland, United States

    Postdoctoral Scientist – Cancer Research Cluster

    Cedars-Sinai – Los Angeles, California, United States

    Post Doctoral Fellow – Autoimmunity and Transplantation

    University of Missouri – Columbia, Missouri, United States

    Research Associate – Recombinant Protein

    Creative Biolabs – New York, New York, United States

    Postdoctoral Project Research Scientist – Signaling and Structural Laboratory

    Francis Crick Institute – London, England, United Kingdom
    Brought to you by

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter